Immunovant (IMVT) director sells 1,500 shares after option exercise

Rhea-AI Filing Summary

Immunovant, Inc. director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. He exercised 1,500 stock options at $8.43 per share and sold 1,500 common shares at an average price of $38.01 per share pursuant to a Rule 10b5-1 plan adopted on December 26, 2025.

Following these transactions, he holds 116,731 common shares directly, 20,000 common shares indirectly through a trust, and 68,181 stock options (right to buy) remaining.

Insider Trade Summary 10b5-1

Net Seller: 1,500 shares ($57,015)

Net Sell 4 txns

Insider Pande Atul

Role null

Sold 1,500 shs ($57K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	1,500	$0.00	--
Exercise	Common Stock	1,500	$8.43	$13K
Sale	Common Stock	1,500	$38.01	$57K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 68,181 shares (Direct, null); Common Stock — 118,231 shares (Direct, null); Common Stock — 20,000 shares (Indirect, By Trust)

Footnotes (1)

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Shares sold: 1,500 shares Sale price: $38.01 per share Option exercise size: 1,500 shares +5 more

8 metrics

Shares sold 1,500 shares Common Stock open-market sale on June 26, 2026

Sale price $38.01 per share Average price for 1,500 common shares sold

Option exercise size 1,500 shares Stock Option (right to buy) exercised into common stock

Option strike price $8.43 per share Exercise price of stock options converted to common stock

Direct common holdings 116,731 shares Common Stock held directly after transactions

Indirect common holdings 20,000 shares Common Stock held indirectly by trust after transactions

Remaining stock options 68,181 options Stock Option (right to buy) balance after exercise

Rule 10b5-1 plan adoption date December 26, 2025 Date pre-planned trading arrangement was adopted

Key Terms

Rule 10b5-1 Plan, Stock Option (right to buy), open-market sale, derivative exercise/conversion, +1 more

5 terms

Rule 10b5-1 Plan financial

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy) with 1,500 shares"

open-market sale financial

"transaction_action: open-market sale of 1,500 Common Stock shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion of stock options"

fully vested financial

"Reflects an award of stock options to purchase Common Shares that is fully vested"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 07:43 PM Accepted by SEC EDGAR 06/26/2026 - 07:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pande Atul

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		M(1)		1,500	A	$8.43	118,231	D
Common Stock	06/26/2026		S(1)		1,500	D	$38.01	116,731	D
Common Stock								20,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.43	06/26/2026		M(1)			1,500	(2)	11/19/2029	Common Stock	1,500	$0	68,181	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Atul Pande	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Immunovant (IMVT) director Atul Pande report?

Immunovant director Atul Pande exercised 1,500 stock options and sold 1,500 common shares. The sale was reported as an open-market transaction at an average price of $38.01 per share, paired with option exercises at a strike price of $8.43 per share.

At what prices did Atul Pande exercise and sell Immunovant (IMVT) shares?

Atul Pande exercised 1,500 stock options with a strike price of $8.43 per share and sold 1,500 common shares at an average price of $38.01. This reflects a typical exercise-and-sell pattern converting option value into cash.

How many Immunovant (IMVT) shares does Atul Pande hold after this Form 4?

After the reported transactions, Atul Pande holds 116,731 Immunovant common shares directly and 20,000 shares indirectly through a trust. He also retains 68,181 stock options, providing additional potential future ownership if exercised.

Were Atul Pande’s Immunovant (IMVT) share sales pre-planned under Rule 10b5-1?

Yes. The filing states the reported sale occurred under a Rule 10b5-1 trading plan adopted on December 26, 2025. Such pre-planned arrangements schedule trades in advance, reducing the significance of short-term market timing for these transactions.

What type of derivative security did Atul Pande exercise in Immunovant (IMVT)?

He exercised stock options described as a “Stock Option (right to buy)” covering 1,500 underlying common shares at a conversion or exercise price of $8.43 per share. The filing notes this option award is fully vested.

Is Atul Pande’s sale of Immunovant (IMVT) shares large relative to his holdings?

The reported sale involved 1,500 shares, while he holds 116,731 shares directly and 20,000 indirectly through a trust. In this context, the sale represents a small portion of his overall reported equity position in Immunovant.